• OncologyTube
    • 0
      • Title
        User LIVE NOW
      • Logo LIVE NOW
        Title
        User
      • Schedule An Interview
        • Schedule A Remote Interview with OncologyTube
    • Home
    • Trending

    • Sign In

    • Audios and Videos
    • Videos
    • Audios

    • Channels

    • Browse Channels

    • Categories

    • Acute Lymphoblastic Leukemia 5645
    • Acute Myelogenous Leukemia 200
    • Bladder Cancer 67
    • Bone Metastases 2
    • Brain Cancer 59
    • Breast Cancer 223
    • Business Management 3
    • Cervical Cancer 6
    • Chronic Lymphocytic Leukemia 192
    • Chronic Myelogenous Leukemia 43
    • Colorectal Cancer 106
    • COVID-19 27
    • Gastrointestinal Cancer 88
    • General 319
    • Head and Neck Cancers 72
    • Hematologic Malignancies 180
    • Hodgkin Lymphoma 28
    • Immunotherapy 153
    • Kidney Cancer 374
    • Liver Cancer 25
    • Lymphoma 179
    • Melanoma and Skin Cancer 57
    • Multiple Myeloma 459
    • Myeloproliferative Disease 19
    • News 147
    • Non-Hodgkin Lymphoma 76
    • Non-Small Cell Lung Cancer 408
    • Other 241
    • Ovarian Cancer 43
    • Pancreatic Cancer 72
    • Patient Resources 28
    • Pediatric Cancer 3
    • Prostate Cancer 218
    • Sickle Cell 21
    • Small Cell Lung Cancer 71
    • Soft Tissue Sarcoma 10
    • Supportive Care 47
    • Testicular Cancer 2
    • Urology 14
    • Uterine Cancer 7

    • About
    • Contact
    I-O Treatment vs. TKI Treatment | TKI is Still Standard of Care for Good-Risk Patients
    00:00:36

    I-O Treatment vs. TKI Treatment | TKI is Still Standard of Care for Good-Risk Patients

    Eric Jonasch, MD, UT MD Anderson Cancer Center explains I-O Treatment vs. TKI Treatment | TKI is Still Standard of Care for Good-Risk Patients at Annual Meeting 2018

    153 Views
    2 years ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Suggested

    Trending

    Memorial Sloan Kettering Cancer Center Looked at Transcriptomic Signature | Outcomes For Patients Undergoing Antigenic Therapy
    00:00:50

    Memorial Sloan Kettering Cancer Center Looked at Transcriptomic Signature | Outcomes For Patients Undergoing Antigenic Therapy

    Free
    157 Views
    2 years ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Whether TKI & I-O Combinations are superior |  Subgroups That Should Use One Over The Other
    00:00:32

    Whether TKI & I-O Combinations are superior | Subgroups That Should Use One Over The Other

    Free
    209 Views
    2 years ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Assign Genomic & Transcriptomic Features | To Treatment Subtypes to See Predictablity
    00:00:33

    Assign Genomic & Transcriptomic Features | To Treatment Subtypes to See Predictablity

    Free
    81 Views
    2 years ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Understanding Tumor Microenvironment | Using Omics Platforms to Assign Treatment
    00:00:29

    Understanding Tumor Microenvironment | Using Omics Platforms to Assign Treatment

    Free
    113 Views
    2 years ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    • 1 (current)
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7

    Liver Cancer

    Eric J. Lehrer MD, MS @EricLehrer @IcahnMountSinai #ASTRO20 #livercancer The Development of Rib Fractures after Stereotactic Body Radiation Therapy to the Liver Eric J. Lehrer MD, MS @EricLehrer @IcahnMountSinai #ASTRO20 #livercancer The Development of Rib Fractures after Stereotactic Body Radiation Therapy to the Liver
    00:06:27

    Eric J. Lehrer MD, MS @EricLehrer @IcahnMountSinai #ASTRO20 #livercancer The Development of Rib Fractures after Stereotactic Body Radiation Therapy to the Liver

    Free
    2 Views
    2 months ago
    ASTRO
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Zarnie Lwin, MD @zarnielwin @RBWHFoundation LBA41 - LEAP-005: Phase II study of len plus pembro in pts with previously treated AST Zarnie Lwin, MD @zarnielwin @RBWHFoundation LBA41 - LEAP-005: Phase II study of len plus pembro in pts with previously treated AST
    0:07:43

    Zarnie Lwin, MD @zarnielwin @RBWHFoundation LBA41 - LEAP-005: Phase II study of len plus pembro in pts with previously treated AST

    Free
    34 Views
    3 months ago
    ESMO
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    John Bridgewater, MD, Ph.D. @uclcancer #livercancer Phase 2 Study FOENIX-CCA2 and Efficacy and Safety of Futibatinib John Bridgewater, MD, Ph.D. @uclcancer #livercancer Phase 2 Study FOENIX-CCA2 and Efficacy and Safety of Futibatinib
    0:15:00

    John Bridgewater, MD, Ph.D. @uclcancer #livercancer Phase 2 Study FOENIX-CCA2 and Efficacy and Safety of Futibatinib

    Free
    69 Views
    3 months ago
    ESMO
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Marwan Fakih, MD @cityofhope #AACR20 Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study Marwan Fakih, MD @cityofhope #AACR20 Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
    0:08:45

    Marwan Fakih, MD @cityofhope #AACR20 Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study

    Free
    18 Views
    3 months ago
    AACR
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Christopher Jakubowski, MD @HopkinsMedicine #ASCO20 Response to Crizotinib in ROS1 Fusion–Positive Intrahepatic Cholangiocarcinoma Christopher Jakubowski, MD @HopkinsMedicine #ASCO20 Response to Crizotinib in ROS1 Fusion–Positive Intrahepatic Cholangiocarcinoma
    0:14:03

    Christopher Jakubowski, MD @HopkinsMedicine #ASCO20 Response to Crizotinib in ROS1 Fusion–Positive Intrahepatic Cholangiocarcinoma

    Free
    11 Views
    3 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Bruno Sangro, MD, Ph.D. @ClinicaNavarra @Adaptimmune #livercancer The unmet need in HCC patients, the ADP-A2AFP complete response and its potential Bruno Sangro, MD, Ph.D. @ClinicaNavarra @Adaptimmune #livercancer The unmet need in HCC patients, the ADP-A2AFP complete response and its potential
    0:09:49

    Bruno Sangro, MD, Ph.D. @ClinicaNavarra @Adaptimmune #livercancer The unmet need in HCC patients, the ADP-A2AFP complete response and its potential

    Free
    108 Views
    3 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Robin Kate Kelley, MD @UCSF Most effective way to combined a CTL4 inhibitor  with a PDL1 inhibitor Robin Kate Kelley, MD @UCSF Most effective way to combined a CTL4 inhibitor  with a PDL1 inhibitor
    0:04:01

    Robin Kate Kelley, MD @UCSF Most effective way to combined a CTL4 inhibitor with a PDL1 inhibitor

    Free
    458 Views
    4 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Robin Kate Kelley, MD @UCSF Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepato... Robin Kate Kelley, MD @UCSF Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepato...
    0:04:26

    Robin Kate Kelley, MD @UCSF Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepato...

    Free
    5,683 Views
    4 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 - common questions asked - Timothy Heuer Ph.D. - twoXAR Pharmaceuticals @twoX... Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 - common questions asked - Timothy Heuer Ph.D. - twoXAR Pharmaceuticals @twoX...
    0:04:23

    Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 - common questions asked - Timothy Heuer Ph.D. - twoXAR Pharmaceuticals @twoX...

    Free
    17 Views
    4 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 - Timothy Heuer Ph.D. - twoXAR Pharmaceuticals @twoXAR #AACR #livercancer Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 - Timothy Heuer Ph.D. - twoXAR Pharmaceuticals @twoXAR #AACR #livercancer
    0:08:56

    Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 - Timothy Heuer Ph.D. - twoXAR Pharmaceuticals @twoXAR #AACR #livercancer

    Free
    21 Views
    4 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Case Discussion: Immunotherapy for Advanced HCC
    00:08:59

    Case Discussion: Immunotherapy for Advanced HCC

    Free
    12 Views
    8 months ago
    HMP CME
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Novel Agents and Targets in Biliary Cancer
    00:19:27

    Novel Agents and Targets in Biliary Cancer

    Free
    12 Views
    8 months ago
    HMP CME
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    • 1 (current)
    • 2
    • 3

    Copyright 2020 Medicus Networks, Inc. 27574 Commerce Center Drive, Suite 236, Temecula, CA 92592